drugset / Trial / NCT03245424
Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation
Summary
To provide access to ivosidenib monotherapy to patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 1 (IDH1) mutation.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivosidenib | Small molecule | 500 mg | Oral |